Status:

COMPLETED

S100B in Intensive Care Patients With and Without Traumatic Brain Injury

Lead Sponsor:

University of Erlangen-Nürnberg Medical School

Conditions:

Tumor

Brain Injuries

Eligibility:

All Genders

18+ years

Brief Summary

The neurotrophic protein S100B has been promoted as a neuromarker for decades, and to reflect the severity of brain injury. On the other hand, S100B is a tumor marker. The interpretation of its serum ...

Detailed Description

Patients of the Department of Neurosurgery, University of Erlangen-Nuremberg, undergoing surgery for sellar lesions were prospectively included. The study protocol was approved by the local Ethical Co...

Eligibility Criteria

Inclusion

  • patients of the Department of Neurosurgery, University of Erlangen Nürnberg, patients with traumatic brain injury,
  • patients with intracranial tumor,
  • intensive care patients,
  • informed written consent was given by the Patient or the next of kin in each case.

Exclusion

  • age under 18
  • pregnancy

Key Trial Info

Start Date :

July 1 2007

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 30 2019

Estimated Enrollment :

600 Patients enrolled

Trial Details

Trial ID

NCT04501315

Start Date

July 1 2007

End Date

June 30 2019

Last Update

August 6 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.